Compare Plby Group Inc (PLBY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Smith & Nephew plc — how do they compare? Plby Group Inc trades at $1.28 (market cap $143.34M), while Smith & Nephew plc trades at $29.95 (market cap $12.71B). The key difference: Smith & Nephew plc is far larger — about 88.7× Plby Group Inc's market cap, and Smith & Nephew plc pays a 2.59% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| PLBY | SNN | |
|---|---|---|
Market Cap | $143.34M | $12.71B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $38.70 |
52-Week Low | $1.11 | $28.73 |
Enterprise Value | $291.14M | $15.48B |
Dividend Yield | — | 2.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.23, up 5.13% today, amid a bearish technical signal. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable. Recent developments include inclusion in the Russell 2000 and 3000 indices and a major share repurchase. Analyst consensus is strongly bullish with 75% buy ratings, reflecting optimism around the company's strategic focus on licensing, media, and experiences.
The outlook for PLBY hinges on sustaining its operational turnaround and achieving profitability. Key opportunities include brand monetization and cost management, while risks involve high debt levels and competitive pressures. Investors should weigh the strong analyst support against the company's historical losses and current negative equity position.
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
